Compare Abbott Laboratories (ABT) vs Bank of America Corp (BAC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Bank of America Corp — how do they compare? Abbott Laboratories trades at $95.66 (market cap $166.94B), while Bank of America Corp trades at $58.53 (market cap $424.80B). The key difference: Bank of America Corp is far larger — about 2.5× Abbott Laboratories's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | BAC | |
|---|---|---|
Market Cap | $166.94B | $424.80B |
Sector | Health | Financials |
52-Week High | $136.62 | $59.90 |
52-Week Low | $82.57 | $44.92 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | 1.87% |
Volume | — | 55,637,172 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Bank of America (BAC) trades at $59.9, up 1.99% today, near the analyst consensus price target of $63.79. The stock shows strong technical momentum with a bullish moving average signal, though RSI levels indicate potential overbought conditions. Fundamentally, BAC delivered three consecutive quarterly earnings beats, with Q1 2026 EPS of $1.11 exceeding expectations. Revenue grew to $113.1 billion in 2025, and the net income margin improved to 26.97%. Recent news highlights strategic partnerships and a focus on talent acquisition.
BAC presents a favorable outlook with robust earnings growth, a dominant deposit franchise, and positive analyst sentiment (64.8% buy ratings). Key opportunities include potential capital returns post-stress tests and AI-driven efficiency gains. Risks involve interest rate sensitivity, macroeconomic pressures on lending, and regulatory changes. The stock's current valuation (P/E 14.86) appears reasonable relative to historical performance, supporting a constructive view for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Bank of America Corp
Bank of America Corporation operates as a financial holding company. The Company offers saving accounts, deposits, mortgage and construction loans, cash and wealth management, certificates of deposit, investment funds, credit and debit cards, insurance, mobile, and online banking services. Bank of America serves customers worldwide.
Read more on BAC →
